Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

Galmed Pharmaceuticals stock opened at $0.29 on Friday. The firm has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.37. The firm has a market capitalization of $1.46 million, a PE ratio of -0.12 and a beta of 0.69. Galmed Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $5.47.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) EPS for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.